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Co(III) complex with a 2-hydrazonylthiazole ligand was synthesized and characterized by single 
crystal X-ray diffraction. In the inner sphere of the complex two monoionic ligands are 
coordinated tridentate forming octahedral geometry around Co(III). Activity of the complex was 
investigated on MCF-7 breast cancer cell line, with cisplatin (CDDP) as a reference compound. 
Results showed that after 24 h incubation Co(III) complex revealed stronger cytotoxic activity 
compared to CDDP. Treatment of MCF-7 3-D cell model with the complex at 10 µM 
concentration achieved complete suppression of spheroid growth in almost the same extent as at 
100 µM. In combination treatments on MCF-7 spheroids, the complex acted synergistically with 
CDDP, while additive interaction type was achieved when the complex was applied together 
with paclitaxel. 
 
Keywords: Thiazoles; Co(III) complex; X-ray diffraction; Anticancer activity; Three drug 
combination study 
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1. Introduction 
Thiazole ring system is a pharmachophore found in major natural and synthetic biologically 
active compounds [1]. A vast number of 1,3-thiazole-based compounds were used as ligands due 
to their ability to coordinate various metal ions [2]. The coordination ability of 1,3-thiazole-
based ligands is attributed to the presence of sulfur and nitrogen in the five-membered thiazole 
ring, but coordination capacity can be enhanced by structural modification and introduction of a 
variety of substituents with suitable donors [2]. (Thiazol-2-yl)hydrazones are a class of thiazoles 
which can be prepared by Hantzsch’s reaction of thiosemicarbazones and α-haloarylcarbonyl 
compounds [2]. They showed antituberculosic, antifungal, antibacterial, antiparasitic, antioxidant 
and anticancer activities [3-7], and potent inhibitory activities against human monoamine 
oxidase B and histone acetyltransferase [8-10]. In this study, Co(III) complex with (thiazol-2-
yl)hydrazone based HL (HL = 2-(2-pyridine-2-ylmethylene)hydrazinyl)-4-(4-tolyl)-1,3-thiazole) 
was synthesized. Apart from being a chemical element essential for normal metabolic function 
and a key substituent in Vitamin B12, cobalt was chosen as the central metal ion since its 
complexes often possess higher activities than cisplatin (CDDP) [11]. HL and its Co(III) 
complex were characterized by elemental analysis, nuclear magnetic resonance (NMR) and 
infrared (IR) spectroscopy, as well as single-crystal X-ray diffraction analysis. In this study we 
review results on anti-cancer activity of the Co(III) complex against human breast cancer MCF-7 
cell line. Investigation has been performed on standard monolayer two-dimensional (2-D) cell 
culture model, and on three-dimensional (3-D) spheroid model which serves as a screening 
platform known to provide more reliable and meaningful therapeutic readouts compared to 2-D 
tests [12]. Also, activities and type of drug interactions on 3-D model subjected to combination 
treatment with Co(III) complex and CDDP or paclitaxel, as well as all three drugs in 
combination were evaluated. This is the first three-drug combination study carried out on a 3-D 
cell culture to date. 
 
2. Experimental 
2.1. General remarks 
Thiosemicarbazide (99%), 2-pyridinecarboxaldehyde (99%) and 2-bromo-4'-
methylacetophenone were obtained from Acros Organics (BVBA, Geel, Belgium). Cobalt 
tetrafluoroborate hexahydrate was obtained from Aldrich (Sigma-Aldrich Chemie GmbH, 
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Steinheim, Germany). All solvents (reagent grade) were obtained from commercial suppliers and 
used without purification. Elemental analyses (C, H and N) were performed by the standard 
micromethods using the ELEMENTARVario ELIII C.H.N.S=O analyzer. Infrared (IR) spectra 
were recorded on a Thermo Scientific Nicolet 6700 FT-IR spectrophotometer by the attenuated 
total reflection (ATR) technique from 4000–400 cm–1. Molar conductivity measurement was 
performed at ambient temperature on a Crison Multimeter MM41. The 1-D (1H and 13C) and 2-D 
NMR spectra were performed on Bruker Avance 500, equipped with a broad-band direct probe. 
All spectra were measured at 298 K. Chemical shifts are given on δ scale relative to 
tetramethylsilane (TMS) as internal standard for 1H and 13C. Atom numbering used in NMR is 
shown in scheme 1. 
 
2.2. Synthesis of (E)-2-(2-(pyridine-2-ylmethylene)hydrazinyl)-4-(4-tolyl)-1,3-thiazole (HL) 
2-Formylpyridine thiosemicarbazone (Hfptsc) was synthesized according to the reported 
literature procedure [6]. 2-Bromo-4'-methylacetofenone (0.1928 g, 8.1 mmol) was added into 
suspension of Hfptsc (0.1460 g, 8.1 mmol) in 20 mL H2O / EtOH mixture (1 : 1, v/v) and stirred 
for 3 h at room temperature. Yellow precipitate was filtered off and washed three times with H2O 
and EtOH. Single crystals of HL suitable for single crystal X-ray diffraction were obtained by 
slow diffusion of MeCN vapour into DMSO solution of raw product. Crystals were filtered off 
and washed with cold MeCN. Yield: 0.150 g (63%). Anal. Calcd for C16H14N4S (%): C, 65.28; 
H, 4.79; N, 19.09; S, 10.89. Found: C, 65.46; H, 4.84; N, 18.99; S, 10.46. IR (ATR, νmax/cm‒1): 
3176 (w), 3109 (w), 3066 (w), 2930 (w), 2850 (w), 2717 (m), 1599 (m), 1573 (vs), 1478 (s), 
1456 (w), 1431 (w), 1407 (w), 1360 (w), 1298 (w), 1271 (vs, 1148 (s), 1115 (w), 1089 (w), 
1047 (m), 1000 (m), 913(m), 879 (w), 839 (w), 789 (w), 766 (w), 726 (m), 681 (m), 637 (w). 
1H NMR (500.26 MHz, DMSO-d6), δH: 2.31, (s, 3H, H‒C16), 7.21 (d, 2H, H‒C6 = H‒C8, 3J6,5 = 
3J8,9 = 8.0 Hz), 7.27 (s, 1H, H‒C2), 7.34 (m, 1H, H‒C14), 7.75 (d, 2H, H‒C5 = H‒C9, 3J5,6 = 
3J9,8 = 8.0 Hz), 7.84 (m, 1H, H‒C12), 7.85 (m, 1H, H‒C13), 8.07 (s, 1H, H‒C10), 8.57 (m, 1H, 
H‒C15), 12.40 (br.s, N‒H). 13C NMR (126.0 MHz, DMSO-d6) δC: 20.78 (C16), 103.22 (C2), 
119.13 (C12), 123.57 (C14), 125.46 (C5 = C9), 129.18 (C6 = C8), 131.91 (C4), 136.88 (C7), 
136.88 (C13), 141.41 (C10), 149.43 (C15), 150.71 (C3), 153.24 (C11), 167.70 (C1). 
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2.3. Synthesis of [Co(L)2]BF4 (1) 
Into suspension of HL (0.10 g; 0.34 mmol) in 20 mL of MeOH, solid Co(BF4)2·6H2O (0.58 g, 
0.17 mmol) was added and the rotten cherry solution was refluxed for 1 h. After two days 
emerald colored single crystals of 1 were filtered off, washed with cold MeOH and Et2O. Yield: 
0.07 g (57%). Anal. Calcd for C32H26N8S2CoBF4 (%): C, 52.47; H, 3.58; N, 15.30; S, 8.76. 
Found: C, 52.46; H, 3.39; N, 15.40; S, 8.84. ΛM (1 × 10‒3 M, MeOH) = 89.10 Ω‒1 cm2 mol‒1. IR 
(ATR, νmax/cm‒1): 3548 (w), 3128 (w), 3074 (w), 1603 (m), 1570 (w), 1533 (s), 1486 (m), 
1444 (w), 1400 (vs), 1346 (vs), 1326 (w),1245 (s), 1136 (w), 1055 (m), 935 (w), 906 (m), 
846 (w), 811 (m), 766 (m), 676 (w), 637 (w). 1H NMR (500.26 MHz, DMSO-d6) δH: 2.46 (s, 3H, 
H‒C16), 6.50 (s, 1H, H‒C2), 6.64 (d, 2H, H‒C6 = H‒C8, 3J6,5 = 3J8,9 = 8.0 Hz), 7.21 (d, 2H, 
H‒C5 = H‒C9, 3J5,6 = 3J9,8 = 8.0 Hz), 7.28 (ddd, 1H, H‒C13, 3J13,12 = 5.7 Hz, 3J13,14 =7.4 Hz), 
7.65 (dd, 1H, H‒C14, 3J14,15 = 7.9 Hz), 7.82 (s, 1H, H‒C10), 7.84 (d, 1H, H‒C12, 3J12,13 = 
5.7 Hz), 7.99 (td, 1H, H‒C15, 3J15,14 = 7.9 Hz). 13C NMR (126.0 MHz, DMSO-d6) δC: 21.19 
(C16), 107.98 (C2), 123.22 (C12), 125.98 (C14), 128.22 (C5 = C9), 128.66 (C6 = C8), 128.84 
(C4), 138.90 (C7), 139.35 (C13), 141.01 (C10), 148.01 (C15), 149.12 (C3), 159.91 (C11), 
180.43 (C1). 
 
2.4. X-ray crystallography 
Single crystal X-ray diffraction was performed on an Oxford Diffraction Gemini S kappa 
geometry diffractometer, equipped with Mo Kα radiation (λ = 0.710689 Å) from a sealed tube 
source, and a Sapphire CCD detector. Data collection strategy calculation, data reduction, cell 
refinement and absorption correction were performed with CRYSALISPRO [13]. The structure 
was solved using SHELXT [14] and refined with anisotropic displacement parameters for all 
non-hydrogen atoms using SHELXL-2014/6 [15]. Program SHELXLE [16] was used as 
graphical user interface for structure solution and refinement procedures. Hydrogens bonded to 
carbons in HL and 1 were introduced in idealized positions and refined using a riding model. 
Hydrogens bonded to nitrogen were located by difference Fourier synthesis and refined using 
distance restraints with Uiso approximated by 1.2Ueq of the parent atoms in HL. Complex 1 was 
found to crystallize in non-centrosymmetric space group. The absolute configuration is 
determined by the Flack-parameter [17]. Structures were validated using PLATON [18] and 
Cambridge Structural Database (v. 5.37, updates Feb. 2016) [19] using MERCURY CSD [20]. 
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2.5. Biological experiments 
2.5.1. Cell cultures. Human mammary adenocarcinoma (MCF-7, ATCC® HTB-22) cell line 
was maintained in DMEM high glucose medium (Dominique Dutscher, 67172 Brumath cedex, 
France, Cat. No. L0102-500), supplemented with heat-inactivated 10% (v/v) fetal bovine serum 
(FBS, Life Technologies, Paisley, UK, Cat. No. 10270-106) and 1% (v/v) penicillin-
streptomycin (10,000 units mL–1 and 10,000 µg mL–1, Life Technologies, Paisley, UK, Cat. No. 
15140-122). Cells were kept at 37 °C in humidified atmosphere containing 5% (v/v) CO2 during 
their exponential growing phase and in the course of incubation with investigated compounds. 1 
was initially dissolved in DMSO to the stock concentration of 20 mM, whereas CDDP and 
starting cobalt salt were dissolved in phosphate buffer saline (PBS) to the stock concentration of 
5 mM. Further dilutions of the compounds were performed with DMEM medium immediately 
before each experiment. HL could not be tested due to low solubility in the culture medium. 
 
2.5.2. Annexin-V / propidium iodide (PI) double staining and determination of ED50 
concentrations on 2-D tumor model. MCF-7 cells were seeded in flat bottom 96 well plates 
(BD Falcon, Cat. No. 353072) at a density of 10,000 cells per 0.1 mL of media. Next day, 
CDDP, 1 and starting cobalt salt were added in a range of six concentrations (1–100 µM), in a 
volume of 0.1 mL. For controls, non-treated cells, cells treated with 0.5% DMSO and cells 
treated with 50 µM Celastrol (Enzo Life Sciences, Farmingdale, US) were used. After 24 h of 
incubation, supernatant with non-adherent cells were removed to another plate. Fresh PBS was 
added to remaining adherent cells; afterwards plates were centrifuged on 450 g for 10 min. 
Supernatant was discarded and 200 µL of trypsin-EDTA (BioWest, Nuaille, France, Cat. No. 
L0930-100) was added to each well. Cells were detached in about 15 min of incubation at 37 °C; 
afterwards another spinning cycle with supernatant elimination was performed. Finally, 
previously removed supernatant with non-adherent cells were added to trypsinized cells and 
stained with Annexin-V-FITC (Immuno Tools, Friesoythe, Germany, Cat. No. 31490013) and PI 
(Miltenyl Biotec Inc., Auburn, USA, Cat. No. 130-093-233) in volumes of 3 µL. Plates were 
analyzed on a Guava EasyCyteTM micro-capillary flow cytometer (Millipore, Merck, Darmstadt, 
Germany) using InCyte® software package. Percentages of all cell death events (Annexin-V 
single-stained, PI single-stained and double-stained cells) were summarized for each of the six 
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concentrations. The computed percentages were plotted against corresponding concentrations on 
a concentration-response graph. ED50 concentration was calculated as the one that corresponds to 
half-way of the sigmoidal concentration-dependent curve using asymmetric five-parameter 
logistic equation (GraphPad Prism 6 software). 
 
2.5.3. Evaluation of a single-drug activity on 3-D tumor model. 3-D MCF-7 mamospheres 
were made in 96 well plates (Corning, Sigma-Aldrich, St. Louis, MO, USA, Cat. No. 4515). 
Tumors were left to grow for an additional four days; afterwards CDDP and 1 were added in 
concentrations of 100, 10 and 1 µM. Evaluation has been maintained during an eight day 
incubation period, with media exchanged on day four. Changes in the tumor sizes have been 
assessed on a Celigo® imaging cytometer (Cyntellect, Brooks Life Science Systems, Poway, CA, 
USA) using Celigo software. Spheroid areas were determined using Celigo software, and growth 
rates were computed for every other day of incubation by dividing the area on the day-n with the 
area on the day 0. 
 
2.5.4. Evaluation of a combination drug activity on 3-D tumor model. Spheroids were 
prepared as described above, and after four days growth drugs were added in combinations. 
Complex 1 was tested in combination with CDDP and paclitaxel, respectively, and together as a 
three drug combination, with the single-drug treated spheres as positive controls for each drug in 
a combination. Treatments lasted for eight days with exchange of media on the fourth day. 
Changes in sizes of spheres were assessed as described above for days zero, four, and eight of 
incubation. Computed growth rates for day eight were used to determine the type of interaction 
between drugs in combinations expressed as combination indexes (CI) using CalcuSyn software 
(Biosoft, Cambridge, United Kingdom). The CI value defines the type of interaction between 
drugs as following: for CI < 0.9 interaction is synergistic, for 0.9 < CI < 1.1 interaction is 
additive, and for CI >1.1 interaction is antagonistic. 
 
3. Results and discussion 
3.1. Synthesis and spectroscopic characterization 
Preparation of HL hydrogen bonded Z-isomer was previously published [6]. In this work 
E-isomer of the HL ligand was prepared by Hantzsch’s reaction of Hfptsc and 2-bromo-4′-
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methoxyacetophenone in a H2O/EtOH mixture (scheme 1). By reaction of HL and 
Co(BF4)2·6H2O in MeOH, [Co(L)2]BF4 (1) was obtained (scheme 1). HL and 1 are soluble in 
DMF and DMSO at room temperature, and in EtOH, MeOH and MeCN at elevated temperature. 
Results of the elemental analysis suggested that in 1 there are two deprotonated ligand 
molecules, cobalt ion and one tetrafluoroborate. The composition of 1 is in accord with the result 
of conductivity measurement. 
The IR spectrum of HL (figure S1, Supplementary data) contains several characteristic 
bands. The band at 3176 cm–1 can be attributed to ν(N‒H). The ligand exhibits a broad band 
around 2700 cm–1 which is assigned to the intermolecular H-bonding vibrations noticed in the 
solid state (vide infra). Bands at 1599 and 1573 cm‒1 are assigned to ν(C=N) of azomethine 
group and thiazole ring, respectively. Coordination of azomethine nitrogen can be assumed on 
the basis of the shift of the band originating from ν(C=N) of azomethine toward higher frequency 
in the complex (1603 cm–1), while the band originating from ν(C=N) of thiazole ring is shifted to 
lower frequency in the IR spectrum of the complex (1533 cm–1). The intensities of these bands 
decreased. Also, in the IR spectrum of the complex (figure S2, Supplementary data) a strong 
band at 1055 cm−1, originating from non-coordinated tetrafluoroborate, can be seen. 
HL and 1 were characterized by 1H and 13C NMR spectroscopy (figures S3–S6, 
Supplementary data) with spectral data given in the Experimental Section. In 1H NMR spectrum 
of 1 the signal from H‒N proton (at 12.40 ppm in the ligand) is missing, indicating coordination 
of the ligand in its deprotonated form. Coordination via nitrogen from thiazole ring could be 
evidenced by strong upfield 1H NMR shift of H–C2 and also by downfield of 13C NMR shift of 
C1 and C2 signals with respect to the ligand. Azomethine nitrogen coordination is supported by 
the upfield shift of H–C10 proton and downfield shift of C11 signals, while pyridine nitrogen 
coordination can be evidenced by upfield shifts of H–C13 and H–C15 protons and downfield 
shift of C13 signal with respect to the ligand. 
 
3.2. Crystal structure analysis 
Crystal data and refinement results for HL and 1 are summarized in table 1, while molecular 
structures are depicted in figure 1. The ligand is planar within 0.18 Å and adopts a conformation 
in which pyridine N4 and azomethine N3, and azomethine N3 and thiazole N1 are mutually in 
trans positions [figure 1(a)]. This implies conformational rearrangement is necessary for 
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tridentate metal binding. Crystal structure of HL [figure 1(b)] is dominated by hydrogen bonds 
between the N4H groups and pyridine nitrogen that give 1-D chains along the b-axis. The 
stacking interactions between neighboring pyridine and tolyl fragments expand these 1-D chains 
into 2-D supramolecular layers parallel to (001) [figure 1(c), table 2]. 
Spontaneous resolution of the racemate occurs during crystallization of 1, so that the 
compound crystallizes as a mixture of enantiopure crystals (conglomerate) in non-
centrosymmetric space group P212121. Thus, each individual crystal contains only one optical 
isomer of [CoL2]+. Octahedral complex cation in 1 is comprised of two meridionally placed 
ligand molecules chelating Co(III) and possesses approximate two-fold symmetry [figure 2(a)]. 
HL molecules are coordinated in an anionic form as tridentate NNN donors, through the 
pyridine, azomethine and thiazole nitrogens. Distortion from an ideal octahedral geometry in 1 is 
imposed by the ligands’ bite angles. In the crystal structure of 1 [figure 2(b)], in addition to the 
electrostatic attraction, cations and tetrafluoroborate anions are connected through hydrogen 
bonds (table 2). 
 
3.3. Comparison of anticancer activity on 2-D and 3-D cell models 
Investigation on anti-cancer activity of 1 was initiated by evaluation of its ability to induce cell 
death in a classical MCF-7 2-D monolayer culture over 24 h of incubation. CDDP was chosen as 
our reference compound, as it is currently the most efficient metal complex administered in 
treatments of various types of cancer [21]. The activity of HL could not be tested due to its low 
solubility in the cell culture medium. Starting cobalt salt after 24 h of incubation exhibited very 
low cytotoxic activity and did not reach ED50 value in the range of applied concentrations (up to 
100 μM). As represented in figure 3, treatment with 1 induced higher incidence of cell death 
compared to CDDP. Contrary to CDDP, activity of 1 displayed a wide plotted concentration-
response curve. This implies there is a broad concentration of 1 to achieve the desired treatment 
effect while avoiding a toxic threshold, i.e. a characteristic of a drug of good therapeutic index 
[22]. 
The next step was to examine the activity of 1 and CDDP in a 3-D cell model. 3-D 
culture models are in vitro derived tissues which mimic in vivo tumors with respect to gradient of 
nutrients, oxygen and metabolites within themselves [23]. Therefore, 3-D models serve as a 
screening platform for drug effectiveness in a function of multiple parameters such as drug 
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concentration, molecular weight, kinetics, charge, solubility, diffusion, metabolism, and 
sequestration [24]. Changes in 3-D cultures can be analyzed regarding two parameters: size and 
morphology. Due to insufficiency of mass transport through cellular barriers, there are three 
concentric zones clearly distinguished within newly developed spheroid: necrotic core (black 
circle located in the center of sphere, consisting of dead cells), quiescent zone (transparent dark 
gray rim that surrounds necrotic core), and proliferating zone (transparent light gray located on 
the outer edge). Sizes and mutual ratio of these zones altered over the days of incubation, thus in 
non-treated spheroids necrotic core is getting bigger with quiescent zone significantly thinned 
and completely suppressed to the very edge of the sphere (figure 4). 
Spheroids treated with CDDP showed concentration-dependent changes in both 
parameters (figure 4). Concentration of 100 µM induced reduction in spheroid size after second 
day of incubation, together with markedly expanded necrotic core and loss of proliferating zone. 
Size of those spheroids remained unchanged over the time of incubation, but zones became 
unrecognizable with development of strikingly crispy edges. CDDP at concentration of 10 µM 
induced growth regression almost equivalent to that achieved with 100 µM, but morphological 
transformation was far less prominent. Thus, on the fourth day, 3-D cultures subjected to 
concentration of 10 µM still had a well-defined edge and preserved thin proliferation zone. 
Spheroids incubated with 1 µM of CDDP were the least affected in both growth rate and 
morphological changes. 
The highest (100 µM) applied concentration of 1 initially induced an increase in size of 
3-D culture accompanied with complete loss of recognizable zones within its architecture, 
demonstrating mighty drug activity. Starting on the fourth incubation day, those spheroids were 
displaying a decrease in size, thus on day eight, their growth rate was almost equal to the one 
obtained after CDDP treatment at the same concentration (1.08 ± 0.03 and 0.95 ± 0.01 for 1 and 
CDDP, respectively). Spheroids incubated with a median concentration of 1 (10 µM) were 
gradually losing their zonal segregation. At day two, a necrotic core was still distinctive, while 
the quiescent zone was dark and glazy with complete disappearance of any proliferation rim. 
Two days later, the necrotic core could be barely identified, while on day six, spheroid zonal 
organization was completely obliterated. Nevertheless, those two concentrations of 1 induced 
almost the same activity on 3-D cultures, but morphological transformations registered in 
spheroids treated with concentration of 10 µM were vigorous to a lesser extent. As for CDDP, 
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the lowest tested concentration of 1 (1 µM) did not produce any substantial growth rate 
inhibition. However, due to the delayed growth, the ratio between necrotic core and quiescent 
zone at day eight was approximately the same as seen on day four in control 3-D cultures. 
The differences in response to treatment with 1 on monolayer or spheroids at 10 and 
100 µM provide insight into benefit of drug testing on a 3-D model. Since 2-D culture of 
adherent cells is considered as completely unrealistic formation where all cells are equally 
exposed to applied treatment, it is not surprising that promising results gained from in vitro 
evaluation are frequently not confirmed during in vivo assessment. Here, concentration of 10 µM 
achieved almost the same activity on the 3-D model as concentration of 100 µM on 2D, a result 
completely unforeseen according to percentages of cell death scored with those concentrations 
on 2-D [figures 3 and 4(a)]. Thus, our results confirm that 1 is a compound with potentially high 
therapeutic index, and by careful dose titration, the desired impact should not be compromised 
with side effects. 
 
3.4. Combination treatment 
The strategy of combination treatment implies acting upon different targets in order to improve 
therapeutic effect as well as to interfere with development of drug resistance which tumor cells 
can easily acquire in case of single drug therapy. Major disadvantage of combination treatment 
includes interactions at the level of side effects. Such interaction demands dose reduction for 
each drug given in combination so to avoid serious toxic complications. We evaluated here the 
possibility of interaction of 1 with paclitaxel, one of the most used drugs for treatment of breast 
cancer [25]. On the other hand, CDDP was revealed as effective for the treatment of locally 
advanced breast cancer, metastatic breast cancer and triple-negative breast cancers [26]. 
The least effective concentrations of 1 and CDDP confirmed in the single-treatment 
experiment were used (1 µM, figure 4) in planning of combination treatments in respect of the 
general approach that implies dose reduction of drugs in combination, while paclitaxel was 
investigated in concentration of 1 ɳM also determined as the concentration with lowest activity 
in the tested range between 1-100 ɳM (data not shown). As shown in figure 5, combination of 
paclitaxel with 1 was the least effective when compared to other three combinations. However, 
the true type of interaction within combinations becomes evident when represented by the 
combination index [CI, figure 5(c)]. Combination of 1 with CDDP revealed synergistic 
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interaction whereas 1 in combination with paclitaxel acted additively with less efficient 
inhibition of spheroid growth. CDDP with paclitaxel in combination performed synergistically 
against MCF-7 3-D model, while the addition of 1 to the triple combination did not help to gain 
any improvement of the overall effect of two conventional drugs, but additionally did not reduce 
it either. Different type of interactions defined for 1 and CDDP when they were separately 
combined with paclitaxel remains a strong indication that those two metal complexes do not 
share the same target. Their combination deserves further investigation on this and other 3-D 
models tested in various concentration ratios. 
 
4. Conclusion 
Although HL is a thiazole - a class of organic compounds with high biological activity, its 
activity could not be tested here due to the low solubility in culture medium (of high sodium salt 
content). Reactions with metal ions can influence the solubility of the ligand itself. We have here 
synthesized and characterized a d-metal complex with (thiazol-2-yl)hydrazone ligand. The 
obtained Co(III) complex 1 is a 1:1 electrolyte, soluble in DMSO and used culture medium, thus 
suitable for biological experiments. Anticancer activity of 1 was investigated using the standard 
monolayer 2-D and 3-D spheroid model, where the latter provides more accurate assessment of 
investigated compound’s actual impact on tumor growth inhibition. Our results reveal that 1 is a 
more potent inducer of cell death than CDDP after 24 h incubation on MCF-7 2-D model, 
whereas both drugs achieved inhibition of 3-D MCF-7 spheres growth in almost the same extent 
after eight days of incubation. However, the difference in morphological changes of spheroids 
subjected to CDDP and 1 was the primary indication that those two compounds do not share the 
same mechanism of activity, supported by the results of combination treatment. The evidence 
that these two metal complexes in combination resulted in synergistic interaction might, at first 
glance, discard the assumption stated above. However, their discordant interaction with 
paclitaxel contributed to hypothesize on the diversity of CDDP and 1 mechanisms for their 
anticancer effect. Although this is the first study on anticancer property of 1, current results 
strongly approve its further testing onto other cancer models, especially the underlying 
mechanism of synergistic interaction with CDDP. 
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Appendix A. Supplementary data 
CCDC 1441009 and CCDC 1441010 contain the supplementary crystallographic data for HL and 
1, respectively. This data can be obtained free of charge via 
https://summary.ccdc.cam.ac.uk/structure-summary-form, or from the Cambridge 
Crystallographic Data Centre, 12 Union Road, Cambridge CB2 IEZ, UK; Fax: (+044)1223-336-
033; or E-mail: deposit@ccdc.cam.ac.uk. Supplementary data associated with this article can be 
found in the online version. 
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Table 1. Data collection and refinement parameters for crystal structures of HL and 1. 
 HL 1 
Chemical formula C16H14N4S C32H26BCoF4N8S2 
Formula weight 294.37 732.47 
Temperature (K) 294 294 
Wavelength (nm) 0.71073 0.71073 
Crystal system  Monoclinic Orthorhombic 
Space group P21/c P212121 
a, b, c (Å) 7.9329(4), 8.6465(3), 21.5857(9) 9.8152(3), 15.3902(5), 22.2103(5) 
α, β, γ (°) 90, 99.822(4), 90 90, 90, 90 
V (Å3) 1458.90(11) 3355.04(17) 
Z 4 4 
μ (mm–1) 0.22 0.70 
Crystal size (mm) 0.70 × 0.17 × 0.07 0.20 × 0.14 × 0.09 
 Tmin, Tmax 0.922, 0.986 0.895, 0.946 
No. of measured, 
independent and 
observed [I > 2σ(I)] 
reflections 
12639 
3489  
2755 
13706 
7148 
4887 
Rint 0.026 0.061 
(sin θ/λ)max (Å–1) 0.680 0.683 
R[F2 > 2σ(F2)] 
wR(F2) 
S 
0.041 
0.132  
1.08 
0.074 
0.188 
1.06 
No. of reflections 3489 7148 
No. of parameters 195 436 
Δmax, Δmin (e Å-3) 0.31, –0.37 0.63, –0.69 
Absolute structure / Flack x determined using 1621 quotients 
[(I+)-(I-)]/[(I+)+(I-)][ref. 16] 
Absolute structure 
parameter 
/ –0.018 (12) 
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Table 2. Crystal packing parameters in the crystal structures of HL and 1. 
HL: H-bond parameters     
D‒H···A D‒H (Å) H·· ·A (Å) D· ··A (Å) D‒H···A (°) symmetry operation on A 
N2‒H2···N4 0.87(3) 2.05(3) 2.915(2) 175(2) 1 ‒ x, ½ + y, ½ ‒ z 
HL: π-π interaction parameters     
Cg(I),Cg(J)a  
Cg–Cgb (Å) 
αc (°) β d (°) γ e (°) slippage f (Å) symmetry operation on J 
Cg1, Cg2 
3.7633(10) 
6 16.9 22.6 1.094  ‒1 + x, ‒1 + y, z 
1: H-bond parameters     
D‒H···A D‒H (Å) H·· ·A (Å) D· ··A (Å) D‒H···A (°) symmetry operation on A 
C2‒H2···F3 
C10‒H10···F4 
C10A‒H10A···F1 
C12‒H12···F1 
0.93 
0.93 
0.93 
0.93 
2.44 
2.34 
2.50 
2.48 
3.316(14) 
3.236(11) 
3.405(10) 
3.395(11) 
158 
162 
163 
171 
2 ‒ x,1/2 + y, 3/2 ‒ z 
3/2 ‒ x, 1 ‒ y, ‒1/2 + z 
‒1 + x, y, z 
3/2 ‒ x, 1 ‒ y, ‒1/2 + z 
a Planes of the rings I/J: ring (1) = N(4),C(11),C(12),C(13),C(14),C(15); ring (2) = C(4),C(5),C(6),C(7),C(8),C(9) 
b
 Cg–Cg = distance between ring centroids (Å). 
c
 α = dihedral angle between planes I and J (°). 
d
 β = angle between Cg(I),Cg(J) vector and normal to plane I (°). 
e
 γ = angle between Cg(I), Cg(J) vector and normal to plane J (°). 
f
 Slippage = distance between Cg(I) and perpendicular projection of Cg(J) on ring I (Å). 
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Figure captions 
Figure 1. (a) Perspective view and labeling of the molecular structure of HL. Thermal ellipsoids 
are at the 40% probability level. Selected bond lengths (Å) and angles (°) with SD’s in 
parentheses: N4–C11, 1.342(2); C10–C11, 1.465(2); N3–C10, 1.277(2); N2–N3, 1.3604(19); 
C1–N2, 1.362(2); N1–C1, 1.300(2); S1–C1, 1.7382(17); S1–C2, 1.7231(19); C2–C3, 1.357(2); 
C2–S1–C1, 87.88(8); C1–N1–C3, 109.99(13); N1–C1–N2, 123.79(15); N1–C1–S1, 116.05(12); 
N2–C1–S1, 120.15(12); N3–N2–C1, 116.98(14); C3–C2–S1, 111.26(13); C10–N3–N2, 
117.63(14); N3–C10–C11, 119.78(15). (b) Infinite 1-D chains in the crystal structure of HL 
viewed along the a-axis. (c) 2-D supramolecular layers in the crystal structure of HL viewed 
along the c-axis. 
 
Figure 2. (a) Perspective view and labeling of the molecular structure of [CoL2]+ in 1. Thermal 
ellipsoids are at the 40% probability level. Selected bond lengths (Å) and angles (°) with SD’s in 
parentheses: Co1–N1, 1.938(6); Co1–N1A, 1.949(6); Co1–N3, 1.888(5); Co1–N3A, 1.885(5); 
Co1–N4, 1.954(6); Co1–N4A, 1.937(6); N2–N3, 1.352(9); N2A–N3A, 1.335(8); N3–C10, 
1.290(10); N3A–C10A, 1.280(10); N2–C1, 1.326(10); N2A–C1A, 1.326(9); S1–C1, 1.726(9); 
S1–C2, 1.731(9); S1A–C1A, 1.728(7); S1A–C2A, 1.718(10); N1–C1, 1.356(9); N1–C3, 
1.370(9); N1A–C1A, 1.336(9); N1A–C3A, 1.395(10). (b) Crystal packing in the crystal structure 
of 1 viewed along the a-axis. Hydrogens are omitted for clarity. 
 
Figure 3. Concentration-response curves and ED50 values for 1 (a) and CDDP (b) on 2-D MCF-7 
cell model after 24 h of incubation. Results are presented as percentage of cell death events 
determined by Annexin-V/PI double staining in two independent experiments (open and closed 
circles) and asymmetric five-parameter sigmoidal curve computed for both replicates in 
GraphPad Prism software. 
 
Figure 4. (a) MCF-7 3-D culture changes in growth and morphology induced by the treatment 
with either 1 or CDDP added in three concentrations over the 8-day incubation period. Images 
have been acquired every other day, starting from day 0 on the Celigo imaging cytometer using 
Celigo software. Scale bar: 500 µm. (b) Changes in growth rate of MCF-7 spheroids treated with 
either 1 or CDDP applied in concentrations of 100 µM (open circle), 10 µM (full square), and 
1 µM (open square), and non-treated control (full circle). Growth rate was determined by means 
of spheroid area established with Celigo software, and afterwards computed for every other day 
of the 8-day incubation period by dividing the area on the day-n with the area on the day 0. 
Results are presented as the mean ± SD of two replicates of independent experiments. 
17 
 
Figure 5. (a) MCF-7 3-D culture changes in growth and morphology induced by treatment with 
different combinations of 1, CDDP and paclitaxel. Images have been acquired every other day, 
starting from day 0 on the Celigo imaging cytometer using Celigo software. Scale bar: 500 µm. 
(b) Changes in growth rate of MCF-7 spheroids treated with combination of CDDP and 
paclitaxel (open triangle), combination of 1 and paclitaxel (open circle), combination of 1 and 
CDDP (open square), combination of 1 with CDDP and paclitaxel (closed square), and non-
treated control (full circle). Growth rate was determined by means of spheroid area established 
with Celigo software, and afterwards computed for days 4 and 8 by dividing the area on day-n 
with the area on day 0. Results are presented as the mean ± SD of two replicates of independent 
experiments. (c) Type of interactions between drugs in combination treatments expressed by 
Combination index (CI), where CI < 0.9 indicates synergistic, 0.9 < CI < 1.1 indicates additive, 
and CI >1.1 indicates an antagonistic type of interaction. Results are presented as the mean ± SD 
of two replicates of independent experiments. 
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